ArticleOpen veterinary journal2025
Global dynamics of vaccine effectiveness and genotype shift in porcine circovirus 2: A cross-temporal analysis.
Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The roles and mechanisms of natural compounds in preventing and treating viral reproductive disorders in major economic livestock.Virulence · 2026Review
- Preparation of Monoclonal Antibodies Against Porcine Circovirus Type 2 Capsid Protein and Development of a Blocking ELISA for Detection of the Antibody Against the Virus.Veterinary sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Porcine circovirus type 2 (PCV2) has caused annual economic losses exceeding US$2 billion to the global swine industry, with mortality rates of 5%-20% in unvaccinated herds. Following the 2006 introduction of PCV2a-based vaccines in 2006, genotype dominance shifted sequentially from PCV2a to PCV2b and from 2010 onward to PCV2d. However, a unified, long-term evaluation of how vaccine uptake influences genotype prevalence and viral evolution remains unavailable. Aim: This study aims to quantify the spatio-temporal relationship between vaccine coverage and genotype shifts, compare genotype-specific vaccine-efficacy decay, and identify capsid-protein sites under positive selection in the post-vaccine era. Methods: Annual genotype frequencies (2000-2025) were extracted from OIE surveillance reports, PCV2 cap-gene sequences were retrieved from GenBank, and vaccine-efficacy figures were compiled from peer-reviewed studies. A reproducible pipeline was used to harmonize these streams into three datasets: genotype prevalence, country-level coverage, and time-indexed efficacy. LOESS smoothing and linear mixed-effects models assessed coverage-prevalence associations. The exponential decay parameters (VE-, k) were estimated Results: Vaccine coverage was inversely correlated with PCV2a prevalence ( Conclusion: PCV2 vaccination exerts selective pressure driving genotype succession. The accelerated waning of protection against emergent genotypes and the emergence of escape-associated mutations at key antigenic sites support the development of multivalent vaccines incorporating PCV2d antigens to sustain long-term herd immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.